Benign Liver Tumours
On this page
Direct answer
The three benign liver tumours that matter for NEET-PG are cavernous haemangioma — the commonest, found in up to a fifth of autopsies, diagnosed by peripheral nodular discontinuous arterial enhancement on multiphase CT or MRI, never biopsied; focal nodular hyperplasia (FNH) — a polyclonal hyperplastic response to a vascular anomaly, with a central scar and preserved hepatocyte function; and hepatocellular adenoma — a hormone-driven true neoplasm of young women on oral contraceptive pills, carrying the twin dangers of spontaneous rupture (especially in pregnancy and tumours above 5 centimetres) and malignant transformation. Management is conservative for haemangioma and asymptomatic FNH, while adenoma management is stop the oestrogen, resect lesions larger than 5 centimetres, symptomatic or male-sex tumours, and avoid pregnancy or monitor closely until regressed — with MRI using hepatobiliary contrast usually clinching the diagnosis without a needle.
What you must remember
- Haemangioma rules: most common benign liver lesion (female predominance); peripheral, nodular, discontinuous enhancement with centripetal fill-in on dynamic imaging; biopsy contraindicated because of bleeding; no treatment unless giant (say beyond 10 cm), symptomatic, or diagnostic doubt — enucleation or embolisation then.
- FNH signature: central stellate scar with spoke-wheel arterial pattern, homogeneous uptake, normal hepatocyte function — classically taking up sulphur colloid on old nuclear scans because it contains Kupffer cells; on hepatobiliary-phase MRI it retains contrast (isointense or hyperintense) since it behaves like normal liver.
- Adenoma profile: young women, oral contraceptives, anabolic steroids, obesity, and glycogen storage disease type I; multiple adenomas (>10 defines adenomatosis) and inflammatory subtype (raised CRP and gamma-GT, the commonest subtype) recognised.
- Adenoma dangers: rupture with haemoperitoneum (risk climbs in pregnancy and with size above 5 cm) and malignant transformation — the beta-catenin-activated subtype carries the highest malignant risk, a molecular detail worth one mark.
- MRI discriminates best: gadolinium hepatobiliary agents (such as gadoxetic acid) — FNH retains contrast in the hepatobiliary phase, adenoma washes out (hypointense) — often avoiding biopsy entirely.
- Management algorithm: haemangioma and FNH — reassure and follow; adenoma — stop hormonal exposure, resect if above 5 cm, symptomatic, ruptured, in a man, or diagnostically unstable; emergency rupture goes to angiography and embolisation with resuscitation, not immediate blind resection.
- Simple cysts and biliary hamartomas (von Meyenburg complexes) round off the incidentaloma list — never need surgery, never biopsy the hamartoma, and do not confuse multiple biliary hamartomas with metastases on imaging.
A typical exam case
A 29-year-old woman on combined oral contraceptives for six years has right upper quadrant fullness; ultrasound reports a 7-centimetre segment VI lesion. Multiphase MRI with hepatobiliary contrast shows a homogeneous arterial blush with central scar that retains contrast in the hepatobiliary phase — FNH, which is followed without treatment, with the contraceptive discussion focused on her preference rather than on any proven FNH-hormone link. Had the lesion shown hepatobiliary-phase washout with fat or haemorrhage within, an adenoma would be the working label: the pill is stopped, and because 7 centimetres exceeds the 5-centimetre threshold, elective resection is scheduled, with pregnancy deferred or carefully monitored until the lesion is dealt with. Had she instead presented collapsed with shoulder-tip pain and falling haemoglobin, ruptured adenoma would be suspected — resuscitation, CT and angiographic embolisation first, resection once stable.
Where students slip
The exam separates candidates on the biopsy question: a vascular lesion with peripheral nodular enhancement is a haemangioma, and the correct next step is confirmatory MRI, never fine-needle aspiration — percutaneous biopsy of a haemangioma is a classic "reject this option" answer. The second discriminator is FNH versus adenoma behaviour: FNH is benign, functionally liver-like, safe to leave; adenoma is the one that ruptures and transforms, driven by hormones — mixing their management loses the stem. Third, the 5-centimetre threshold for adenoma resection, the advice to stop oestrogens, and the pregnancy hazard form the three-part answer to "how would you manage a 6 cm hepatic adenoma".
Frequently asked questions
Why is liver haemangioma never biopsied?
Because it is a blood-filled cavernous lesion — percutaneous sampling risks serious haemorrhage, and characteristic imaging (peripheral nodular discontinuous enhancement) makes biopsy unnecessary.
How is focal nodular hyperplasia distinguished from adenoma on imaging?
FNH shows a central stellate scar with homogeneous arterial enhancement and retains hepatobiliary contrast, whereas adenoma shows washout on hepatobiliary-phase MRI, often with fat, haemorrhage or heterogeneity.
What size of hepatocellular adenoma warrants resection?
Adenomas above 5 centimetres are resected because rupture and malignant transformation risks rise with size; smaller asymptomatic adenomas may be observed after stopping hormonal exposure.
What is the emergency presentation of a hepatic adenoma?
Spontaneous rupture with intra-abdominal haemorrhage — sudden pain, shoulder-tip referral and haemodynamic instability, classically in pregnancy or with large tumours — managed by resuscitation and angiographic embolisation before definitive surgery.
Do oral contraceptives cause focal nodular hyperplasia?
No — FNH is a hyperplastic response to a local vascular anomaly; oral contraceptives may marginally enlarge lesions but are not causal, unlike their clear causal link with hepatocellular adenoma.